Increasing Utilization of Cancer Genetic Counseling Services Using a Patient Navigator Model

Overview

Journal J Genet Couns

Publisher Wiley

Specialty Genetics

Date 2007 Feb 6

PMID 17277995

Citations 28

Authors

Alanna Kulchak Rahm

Anna Sukhanova

Jennifer Ellis

Judy Mouchawar

Affiliations

Soon will be listed here.

Abstract

Rarely has utilization of genetic counseling for Hereditary Breast and Ovarian Cancer (HBOC) been studied separately from utilization of testing. At Kaiser Permanente Colorado, consistently only 30% of all members referred for HBOC attend genetic counseling. To increase the volume of genetic counseling appointments, a patient navigator approach was pilot tested in a randomized-controlled trial over 3 months. A total of 125 members were referred for HBOC genetic counseling (55 randomized to PN, 70 randomized to usual care). Utilization of referrals for Navigator-assisted members was 44%, compared to 31% in the usual care arm (p=0.16). The patient navigator significantly decreased time to appointment, with over 80% of Navigator-assisted members seen for genetic counseling less than three months from referral date, compared to 32% in usual care (p=0.002). patient navigator assistance shortens time from referral to appointment for HBOC genetic counseling, and may increase utilization of such services.

Citing Articles

Implementation of a Population-Based Cancer Family History Screening Program for Lynch Syndrome.

Lahiri S, Pirzadeh-Miller S, Moriarty K, Kubiliun N Cancer Control. 2023; 30:10732748231175011.

PMID: 37161761 PMC: 10185972. DOI: 10.1177/10732748231175011.

A practical method for integrating community priorities in planning and implementing cancer control programs.

Bilenduke E, Dwyer A, Staples E, Kilbourn K, Valverde P, Fernandez M Cancer Causes Control. 2023; 34(Suppl 1):113-123.

PMID: 37069456 PMC: 10110487. DOI: 10.1007/s10552-023-01688-w.

Change agents in the oncology workforce: Let's be clear about community health workers and patient navigators.

Battaglia T, Zhang X, Dwyer A, Rush C, Paskett E Cancer. 2022; 128 Suppl 13:2664-2668.

PMID: 35699614 PMC: 9201990. DOI: 10.1002/cncr.34194.

Reducing Disparities in Receipt of Genetic Counseling for Underserved Women at Risk of Hereditary Breast and Ovarian Cancer.

Sutton A, Hurtado-de-Mendoza A, Quillin J, Rubinsak L, Temkin S, Gal T J Womens Health (Larchmt). 2019; 29(8):1131-1135.

PMID: 31794334 PMC: 7462013. DOI: 10.1089/jwh.2019.7984.

Lung Cancer Screening and Epigenetics in African Americans: The Role of the Socioecological Framework.

Watson K, Hulbert A, Henderson V, Chukwudozie I, Aponte-Soto L, Lerner L Front Oncol. 2019; 9:87.

PMID: 30915271 PMC: 6423082. DOI: 10.3389/fonc.2019.00087.

References

Lerman C, Biesecker B, Benkendorf J, Kerner J, Gomez-Caminero A, Hughes C . Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing. J Natl Cancer Inst. 1997; 89(2):148-57. DOI: 10.1093/jnci/89.2.148. View

Escher M, Sappino A . Primary care physicians' knowledge and attitudes towards genetic testing for breast-ovarian cancer predisposition. Ann Oncol. 2000; 11(9):1131-5. DOI: 10.1023/a:1008319114278. View

Reyna V, LLOYD F, Whalen P . Genetic testing and medical decision making. Arch Intern Med. 2001; 161(20):2406-8. DOI: 10.1001/archinte.161.20.2406. View

Julian-Reynier C, Sobol H, Sevilla C, Nogues C, BOURRET P . Uptake of hereditary breast/ovarian cancer genetic testing in a French national sample of BRCA1 families. The French Cancer Genetic Network. Psychooncology. 2001; 9(6):504-10. DOI: 10.1002/1099-1611(200011/12)9:6<504::aid-pon491>3.0.co;2-r. View

Mouchawar J, Hensley-Alford S, Laurion S, Ellis J, Kulchak-Rahm A, Finucane M . Impact of direct-to-consumer advertising for hereditary breast cancer testing on genetic services at a managed care organization: a naturally-occurring experiment. Genet Med. 2005; 7(3):191-7. DOI: 10.1097/01.gim.0000156526.16967.7a. View

Geer K, Ropka M, Cohn W, Jones S, Miesfeldt S . Factors influencing patients' decisions to decline cancer genetic counseling services. J Genet Couns. 2002; 10(1):25-40. DOI: 10.1023/a:1009451213035. View

Mouchawar J, Goins K, Somkin C, Puleo E, Hensley Alford S, Geiger A . Guidelines for breast and ovarian cancer genetic counseling referral: adoption and implementation in HMOs. Genet Med. 2003; 5(6):444-50. DOI: 10.1097/01.gim.0000093979.08524.86. View

Thompson H, Valdimarsdottir H, Guevarra J, Bovbjerg D, Amarel D, Godfrey D . Psychosocial predictors of BRCA counseling and testing decisions among urban African-American women. Cancer Epidemiol Biomarkers Prev. 2002; 11(12):1579-85. View

Acton R, Burst N, Casebeer L, Ferguson S, Greene P, Laird B . Knowledge, attitudes, and behaviors of Alabama's primary care physicians regarding cancer genetics. Acad Med. 2000; 75(8):850-2. DOI: 10.1097/00001888-200008000-00021. View

10.

Frelix G, Rosenblatt R, Solomon M, Vikram B . Breast cancer screening in underserved women in the Bronx. J Natl Med Assoc. 1999; 91(4):195-200. PMC: 2608420. View

11.

Lantz P, Keeton K, Romano L, DeGroff A . Case management in public health screening programs: the experience of the national breast and cervical cancer early detection program. J Public Health Manag Pract. 2005; 10(6):545-55. DOI: 10.1097/00124784-200411000-00012. View

12.

Brooks L, Lennard F, Shenton A, Lalloo F, Ambus I, Ardern-Jones A . BRCA1/2 predictive testing: a study of uptake in two centres. Eur J Hum Genet. 2004; 12(8):654-62. DOI: 10.1038/sj.ejhg.5201206. View

13.

Gardner L, Metsch L, Anderson-Mahoney P, Loughlin A, Del Rio C, Strathdee S . Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS. 2005; 19(4):423-31. DOI: 10.1097/01.aids.0000161772.51900.eb. View

14.

Freeman H, Muth B, Kerner J . Expanding access to cancer screening and clinical follow-up among the medically underserved. Cancer Pract. 1995; 3(1):19-30. View

15.

Armstrong K, Micco E, Carney A, Stopfer J, Putt M . Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA. 2005; 293(14):1729-36. DOI: 10.1001/jama.293.14.1729. View

16.

Calzone K, Prindiville S, Jourkiv O, Jenkins J, DeCarvalho M, Wallerstedt D . Randomized comparison of group versus individual genetic education and counseling for familial breast and/or ovarian cancer. J Clin Oncol. 2005; 23(15):3455-64. DOI: 10.1200/JCO.2005.04.050. View

17.

Armstrong K, Weber B, Stopfer J, Calzone K, Putt M, Coyne J . Early use of clinical BRCA1/2 testing: associations with race and breast cancer risk. Am J Med Genet A. 2003; 117A(2):154-60. DOI: 10.1002/ajmg.a.10928. View

18.

Mouchawar J, Klein C, Mullineaux L . Colorado family physicians' knowledge of hereditary breast cancer and related practice. J Cancer Educ. 2001; 16(1):33-7. DOI: 10.1080/08858190109528721. View

19.

Wideroff L, Freedman A, Olson L, Klabunde C, Davis W, Srinath K . Physician use of genetic testing for cancer susceptibility: results of a national survey. Cancer Epidemiol Biomarkers Prev. 2003; 12(4):295-303. View

20.

Pieterse A, Ausems M, Van Dulmen A, Beemer F, Bensing J . Initial cancer genetic counseling consultation: change in counselees' cognitions and anxiety, and association with addressing their needs and preferences. Am J Med Genet A. 2005; 137(1):27-35. DOI: 10.1002/ajmg.a.30839. View